Achieve Life Sciences (NASDAQ:ACHV) Announces Quarterly Earnings Results, Beats Estimates By $0.11 EPS

Achieve Life Sciences (NASDAQ:ACHV) issued its quarterly earnings data on Tuesday. The biopharmaceutical company reported ($0.19) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.30) by $0.11, FiscalAI reports.

Here are the key takeaways from Achieve Life Sciences’ conference call:

• Achieve said its recent $180 million private placement, with up to $174 million more from milestone warrants, gives the company a strong capital base to pursue approval and launch plans.
• The company expects an FDA complete response letter tied to issues at a prior third-party manufacturer and plans to resubmit the NDA in Q4 2026 with Adare Pharma Solutions as the primary U.S. commercial supply partner.
• Management highlighted encouraging clinical and mechanistic data for cytisinicline, including selective receptor activity that may help explain its low nausea rates and strong efficacy in hard-to-treat patients who previously used varenicline or bupropion.
• Achieve is moving ahead with an independent commercial launch strategy and has added experienced leaders from Verona Pharma, including a new commercial SVP and sales leadership for the field force.
• The company reiterated plans to advance its vaping program, saying it hopes to initiate the ORCA-V2 phase III trial this year while continuing to work with FDA on timelines and trial design.

Achieve Life Sciences Stock Down 3.3%

Shares of ACHV stock traded down $0.20 during trading hours on Wednesday, reaching $5.80. 251,287 shares of the company’s stock were exchanged, compared to its average volume of 970,788. Achieve Life Sciences has a 1 year low of $2.00 and a 1 year high of $6.15. The stock has a market cap of $308.47 million, a PE ratio of -4.46 and a beta of 2.25. The company has a current ratio of 4.39, a quick ratio of 4.39 and a debt-to-equity ratio of 0.52. The stock’s fifty day moving average price is $4.00 and its two-hundred day moving average price is $4.45.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of ACHV. AQR Capital Management LLC acquired a new stake in shares of Achieve Life Sciences during the first quarter worth $32,000. Qube Research & Technologies Ltd acquired a new position in shares of Achieve Life Sciences in the 2nd quarter valued at $232,000. Raymond James Financial Inc. raised its stake in Achieve Life Sciences by 57.1% in the 2nd quarter. Raymond James Financial Inc. now owns 295,058 shares of the biopharmaceutical company’s stock worth $667,000 after acquiring an additional 107,218 shares during the last quarter. Jane Street Group LLC purchased a new position in Achieve Life Sciences in the 2nd quarter worth $159,000. Finally, Bank of America Corp DE lifted its position in Achieve Life Sciences by 39.9% during the 2nd quarter. Bank of America Corp DE now owns 33,731 shares of the biopharmaceutical company’s stock worth $76,000 after acquiring an additional 9,617 shares during the period. Institutional investors and hedge funds own 33.52% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on ACHV. Wall Street Zen upgraded Achieve Life Sciences from a “strong sell” rating to a “sell” rating in a report on Saturday. HC Wainwright reaffirmed a “buy” rating and set a $12.00 price objective on shares of Achieve Life Sciences in a research report on Thursday, April 16th. Canaccord Genuity Group set a $13.00 target price on shares of Achieve Life Sciences and gave the stock a “buy” rating in a report on Monday, April 20th. Finally, Weiss Ratings lowered shares of Achieve Life Sciences from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday. Two research analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Achieve Life Sciences presently has a consensus rating of “Buy” and a consensus target price of $14.67.

Achieve Life Sciences Company Profile

Achieve Life Sciences, Inc (NASDAQ: ACHV) is a clinical-stage biotechnology company dedicated to the development and commercialization of cytisinicline, a plant-derived alkaloid for smoking cessation. The company’s mission is to offer a novel, evidence-based therapy that addresses the global need for effective and well-tolerated smoking cessation options. Achieve focuses its efforts on advancing the clinical profile of cytisinicline through rigorous development programs and regulatory engagement.

Cytisinicline (formerly marketed as Tabex® in Europe) acts as a nicotinic acetylcholine receptor partial agonist, helping reduce withdrawal symptoms and nicotine cravings.